Differentiated approach to the treatment of infectious and inflammatory pathology of the pharynx and tonsils in adults

Abstract

Introduction. The problem of infectious pathology of the pharynx and tonsils, manifested by sore throat, does not lose relevance. In the absence of indications for systemic antibacterial therapy, the main role of etiotropic treatment passes to topical use of drugs, including in the form of gargling. One of these is hydroxymethylquinoxalindioxide (Dioxidin®), which has recently received a new dosage form.Aim. To present an overview of the efficacy and safety of two dosage forms of Dioxidin® in the treatment of infectious and inflammatory pathology of the pharynx and tonsils.Materials and methods. The results of evaluating the efficacy and safety of 0.1% and 0.025% Dioxidine solutions for oropharyngeal rinsing in the treatment of adult patients with acute tonsillopharyngitis (ATP) or exacerbation of chronic tonsillitis (eCT) obtained during controlled comparative multicenter clinical trials conducted in 2017–2020 were analyzed.Results. By day 9 ± 1 of follow-up, relief of all local signs of inflammation according to pharyngoscopy was observed in 87% of patients with ATP or eCT who used 0.1% solution for rinsing and in 84% of patients with ATP who used 0.025% Dioxidine solution for rinsing. The severity of sore throat, assessed using a visual analog scale, by the specified time decreased by 63 points in the group using 0.1% solution and by 50 points according to the study of the effectiveness of 0.025% Dioxidine. 0.1% Dioxidine solution was more effective than 0.02% nitrofuran solution, and at a concentration of 0.025%, the effectiveness of Dioxidine was comparable to 0.01% benzyldimethyl[3-(myristoylamino)solutionpropyl]ammonium chloride. Both studies demonstrated a high level of safety of the two dosage forms of Dioxidine, which has no statistically significant differences from the safety assessments of comparison drugs.Conclusion. The presented data confirm the high efficacy and safety of 0.1% and 0.025% Dioxidin® solutions and suggest the possibility of implementing a differentiated approach to the treatment of inflammatory tonsillar pathology using two dosage forms of the drug.